Who are Nucala's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fasenra, Cinqair, Nucala, Fasenra®, Mepolizumab Injection [Nucala], Mepolizumab 100 milligrams.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mepolizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Nucala — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nucala (MEPOLIZUMAB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interleukin-5 Antagonist [EPC]. Area: Respiratory.

marketed Interleukin-5 Antagonist [EPC] Interleukin-5 Respiratory Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Nucala (MEPOLIZUMAB) — GSK. Nucala works by binding to interleukin-5, a protein that stimulates the production of eosinophils.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nucala TARGET	MEPOLIZUMAB	GSK	marketed	Interleukin-5 Antagonist [EPC]	Interleukin-5	2015-01-01
Fasenra	BENRALIZUMAB	AstraZeneca	marketed	Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]	Interleukin-5 receptor subunit alpha	2017-01-01
Cinqair	RESLIZUMAB	Teva Respiratory Llc	marketed	Interleukin-5 Antagonist [EPC]	Interleukin-5	2016-01-01
Nucala	Nucala	Mayo Clinic	marketed		Interleukin-5
Fasenra®	Fasenra®	AstraZeneca	marketed	IL-5 receptor antagonist monoclonal antibody	IL-5Rα (interleukin-5 receptor alpha)
Mepolizumab Injection [Nucala]	Mepolizumab Injection [Nucala]	KU Leuven	marketed	IL-5 antagonist monoclonal antibody	IL-5 (Interleukin-5)
Mepolizumab 100 milligrams	Mepolizumab 100 milligrams	GlaxoSmithKline	phase 3	IL-5 antagonist monoclonal antibody	IL-5 (Interleukin-5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interleukin-5 Antagonist [EPC] class)

GSK · 1 drug in this class
Teva Respiratory Llc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nucala — Competitive Intelligence Brief. https://druglandscape.com/ci/mepolizumab. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing